FDA 483 - Lupin Limited
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Lupin Limited in Nagpur, India, received a Form FDA 483 with five observations following an inspection on October 20, 2022. The inspection revealed significant deficiencies in aseptic processing areas, including facility surfaces, microbiological contamination prevention procedures, inadequate validation of aseptic processes, and environmental monitoring systems. Additionally, the firm failed to thoroughly review unexplained discrepancies and out-of-specification events related to API shipment and sterility testing.
- Company
- Lupin Limited
- Product Type
- Drugs
ID · 0486e3a3-7887-41ff-9908-811e2a997f4e